Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Taxane chemotherapy plus lapatinib versus taxane chemotherapy plus trastuzumab as first-line therapy for HER2-positive metastatic breast cancer
2007-004568-27Phase 3Completed
- Sponsor
- Novartis
- Start
- Jun 2008
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of lapatinib and trastuzumab in HER2-positive breast cancer (2 arms), sponsored by Novartis. Primary endpoint: Progression-free survival. Started Jun 2008; status: completed.
02
Drugs
lapatinibtrastuzumab
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on 2007-004568-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-004568-27.